The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
D000951:Antigens, Neoplasm / Q000032:analysis*; D000954:Antigens, Surface / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003110:Colonic Neoplasms / Q000276:immunology; D005770:Gastrointestinal Neoplasms / Q000276:immunology*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000276:immunology; D011237:Predictive Value of Tests; D013274:Stomach Neoplasms / Q000276:immunology
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D015295:Antigens, Tumor-Associated, Carbohydrate; D002272:Carcinoembryonic Antigen